Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,233.66
-13.27 (1.06%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
220 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is recognized as a leading player in the healthcare industry, particularly in the GLP-1 drug market, which has driven significant stock performance, up approximately 370% over the past five years. Experts highlight the company’s robust drug pipeline, strong execution, and expansion plans, particularly with the anticipated oral version of its weight-loss drug. Despite these strengths, many analysts warn about current high valuations, suggesting that the stock may be priced to perfection, creating caution around new investments at present levels. While the company has a diversified portfolio beyond GLP-1 drugs, stock performance has recently hit all-time highs, prompting some to advise a strategic wait for pullbacks before making new purchases. Overall, analysts see a positive growth trajectory for Eli Lilly in terms of revenue and earnings, backed by a strong market position and effective management of its drug offerings.

consensus icon
Consensus
Positive
valuation icon
Valuation
Overvalued
review icon
Similar
Amgen,AMGN
BUY

Eli Lilly & Co.(LLY)

Jun 16, 2009
All the pharmaceutical stocks are cheap. He would recommend Johnson & Johnson (JNJ-N) and Merck & Co. (MRK-N) ahead of this one. (See Top Picks.)
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$32.98

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 07, 2009
Pharma is a sector that usually outperforms in times of crisis and in bear markets. They have generally been a good hiding spot. The group will probably lag any uptick in the market. 5.5% dividend.
Photo of Greg A. Taylor, CFA, BBAGreg A. Taylor, CFA, BBAUnlock Rating
$35.85

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Nov 07, 2006
One of the major concerns that pharmacy companies have is patent expiration and generics coming in. Doesn't think they have any major products coming off patents until 2010.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$56.98

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 31, 2006
Hasn't gone anywhere because it hasn't any blockbuster drugs. Has a good pipeline. Demographically, diabetes is set to explode.
Photo of Norman LevineNorman LevineUnlock Rating
$56.01

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Mar 15, 2006
Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$56.97

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 25, 2005
This is a part of the market that's lagging. There has been such a slowdown in the growth rates.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$53.50

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jul 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$56.37

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Eli Lilly & Co.(LLY)

May 03, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$59.75

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Eli Lilly & Co.(LLY)

Mar 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
Photo of George LougheryGeorge LougheryUnlock Rating
$52.70

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Aug 13, 2004
Lots of new products. Rapid profit growth.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$61.57

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 16, 2004
Powerful balance sheet.
Photo of Alan BlakeAlan Blake
Owned
Unlock Rating
$66.30

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Apr 16, 2004
Photo of Richard BernstienRichard Bernstien
Owned
Unlock Rating
$72.45

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Apr 02, 2002
Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$78.74

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$81.54

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Oct 30, 2001
Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J.
Photo of Neil MurdockNeil MurdockUnlock Rating
$77.27

Stock price when the opinion was issued

$1233.66

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 210 of 212 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like